At a glance
ClinicalIndex Comparison Record- ✓Premenopausal women with histologically confirmed breast cancer
- ✓Hormone receptor positive (estrogen and/or progesterone receptor positive, at least 10% of tumor cells positive by immunohistochemistry)
- ✓Completely resected disease with no clinically detectable residual loco-regional axillary disease
- ✓Tumor confined to breast and axillary nodes, no distant metastases
- ✕Prior neoadjuvant or adjuvant chemotherapy
- ✕Prior neoadjuvant or adjuvant endocrine therapy since breast cancer diagnosis
- ✕No locally advanced inoperable breast cancer, inflammatory breast cancer, supraclavicular node involvement, or enlarged internal mammary nodes
- ✕No distant metastases
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer
In Brief
A Phase 3 clinical trial evaluating exemestane, tamoxifen, and 1 other intervention for Breast Cancer. Completed, enrolled 2,672 participants across 228 sites in 17 countries.
Detailed Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen. It is not yet known whether giving triptorelin together with exemestane is more effective than triptorelin and tamoxifen in treating hormone-responsive breast cancer. PURPOSE: This randomized phase III trial is studying triptorelin and exemestane to see how well they work compared to triptorelin and tamoxifen in treating premenopausal women with hormone-responsive breast cancer.